Cargando…
Autoimmune Myopathies: Where Do We Stand?
Autoimmune diseases (AIDs) as a whole represent a major health concern and remain a medical and scientific challenge. Some of them, such as multiple sclerosis or type 1 diabetes, have been actively investigated for many decades. Autoimmune myopathies (AIMs), also referred to as idiopathic inflammato...
Autores principales: | Simon, Jean-Philippe, Marie, Isabelle, Jouen, Fabienne, Boyer, Olivier, Martinet, Jérémie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905946/ https://www.ncbi.nlm.nih.gov/pubmed/27379096 http://dx.doi.org/10.3389/fimmu.2016.00234 |
Ejemplares similares
-
ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011) -
Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies
por: Drouot, Laurent, et al.
Publicado: (2014) -
Translating tolerogenic therapies to the clinic – where do we stand?
por: Issa, Fadi, et al.
Publicado: (2012) -
Editorial: Immune Profile After Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases: Where Do We Stand?
por: Malmegrim, Kelen Cristina Ribeiro, et al.
Publicado: (2020) -
Translating Tolerogenic Therapies to the Clinic – Where Do We Stand and What are the Barriers?
por: Cobbold, Stephen P., et al.
Publicado: (2012)